Abstract
Advances in recombinant DNA technologies have led to the development of longer-acting preparations with prolonged follicle-stimulating bioactivity. Corifollitropin alfa is a synthetic recombinant follicle-stimulating hormone (r-FSH) molecule containing a hybrid beta subunit, which provides prolonged follicle-stimulating activity while maintaining its pharmacodynamic activity. In controlled ovarian stimulation, long-acting gonadotropins have the ability to initiate and sustain multifollicular growth for 7 days. Current evidence suggests that the use of a medium dose of long-acting FSH is a safe treatment option and equally effective compared to daily FSH. This simplified treatment approach may provide a more patient-friendly approach to controlled ovarian stimulation. Further research is needed to determine whether long-acting FSH is safe and efficacious in patients at risk of ovarian hyperstimulation or poor responders. Studies are also needed to assess patient satisfaction and overall patient experience with the long-acting FSH preparations. Novel drug delivery systems developments will ultimately lead to greater ease of administration, more simplified and convenient dosing regimens and superior safety and efficacy, ultimately leading to greater patient satisfaction and improved patient experience.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Edwards RG, Steptoe PC. Induction of follicular growth, ovulation and luteinization in the human ovary. J Reprod Fertil Suppl. 1975;(22):121–63.
Brown JB. Pituitary control of ovarian function--concepts derived from gonadotropin therapy. Aust N Z J Obstet Gynaecol. 1978;18:46–54.
Baird DT. A model for follicular selection and ovulation: lessons from superovulation. J Steroid Biochem. 1987;27:15–23.
Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2006;27:170–207.
Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev. 1997;18:71–106.
Schroder AK, Katalinic A, Diedrich K, Ludwig M. Cumulative pregnancy rates and drop-out rates in a German IVF programme: 4102 cycles in 2130 patients. Reprod Biomed Online. 2004;8:600–6.
Scholtes MC, Schnittert B, van Hoogstraten D, Verhoeven HC, Zrener A, Warne DW. A comparison of 3-day and daily follicle-stimulating hormone injections on stimulation days 1–6 in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2004;81:996–1001.
Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update. 2009;15:309–21.
Chappel SC. Heterogeneity of follicle stimulating hormone: control and physiological function. Hum Reprod Update. 1995;1:479–87.
Stockell Hartree A, Renwick AG. Molecular structures of glycoprotein hormones and functions of their carbohydrate components. Biochem J. 1992;287(Pt 3):665–79.
Amin HK, Hunter WM. Human pituitary follicle-stimulating hormone: distribution, plasma clearance and urinary excretion as determined by radioimmunoassay. J Endocrinol. 1970;48:307–17.
Kohler PO, Ross GT, Odell WD. Metabolic clearance and production rates of human luteinizing hormone in pre- and postmenopausal women. J Clin Invest. 1968;47:38–47.
Matzuk MM, Hsueh AJ, Lapolt P, Tsafriri A, Keene JL, Boime I. The biological role of the carboxyl-terminal extension of human chorionic gonadotropin [corrected] beta-subunit. Endocrinology. 1990;126:376–83.
Weenen C, Pena JE, Pollak SV, Klein J, Lobel L, Trousdale RK, et al. Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with o-linked analogs in female rats. J Clin Endocrinol Metab. 2004;89:5204–12.
Perlman S, van den Hazel B, Christiansen J, Gram-Nielsen S, Jeppesen CB, Andersen KV, et al. Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. J Clin Endocrinol Metab. 2003;88:3227–35.
Klein J, Lobel L, Pollak S, Ferin M, Xiao E, Sauer M, et al. Pharmacokinetics and pharmacodynamics of single-chain recombinant human follicle-stimulating hormone containing the human chorionic gonadotropin carboxyterminal peptide in the rhesus monkey. Fertil Steril. 2002;77:1248–55.
Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci U S A. 1992;89:4304–8.
Ludwig M, Felberbaum RE, Diedrich K, Lunenfeld B. Ovarian stimulation: from basic science to clinical application. Reprod Biomed Online. 2002;5 Suppl 1:73–86.
LaPolt PS, Nishimori K, Fares FA, Perlas E, Boime I, Hsueh AJ. Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides. Endocrinology. 1992;131:2514–20.
Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, Voortman G. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod. 2002;17:1987–93.
Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab. 2004;89:2062–70.
Bouloux PM, Handelsman DJ, Jockenhovel F, Nieschlag E, Rabinovici J, Frasa WL, et al. First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Hum Reprod. 2001;16:1592–7.
Balen AH, Mulders AG, Fauser BC, Schoot BC, Renier MA, Devroey P, et al. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. J Clin Endocrinol Metab. 2004;89:6297–304.
The Corifollitropin Alfa Dose-finding Study Group. A randomized dose–response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation†. Hum Reprod. 2008;23:2484–92.
Devroey P, Boostanfar R, Koper NP, Mannaerts BMJL, Ijzerman-Boon PC, Fauser BCJM. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009;24:3063–72.
The Corifollitropin Alfa Ensure study group. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reprod Biomed Online. 2010;21:66–76.
Pouwer AW, Farquhar C, Kremer JA. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database Syst Rev. 2012;(6):CD009577.
Norman RJ, Zegers-Hochschild F, Salle BS, Elbers J, Heijnen E, Marintcheva-Petrova M, et al. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum Reprod. 2011;26:2200–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer India
About this chapter
Cite this chapter
Das, M., Holzer, H.E.G. (2016). Long-acting Gonadotropins and Route of Administration. In: Allahbadia, G., Morimoto, Y. (eds) Ovarian Stimulation Protocols. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1121-1_6
Download citation
DOI: https://doi.org/10.1007/978-81-322-1121-1_6
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-1120-4
Online ISBN: 978-81-322-1121-1
eBook Packages: MedicineMedicine (R0)